MicroAire SmartRelease Endoscopic System, Endoscopic Carpal Tunnel Release, SmartRelease Handpiec...

FDA Device Recall #Z-2107-2018 — Class II — April 19, 2018

Recall Summary

Recall Number Z-2107-2018
Classification Class II — Moderate risk
Date Initiated April 19, 2018
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm MicroAire Surgical Instruments, LLC
Location Charlottesville, VA
Product Type Devices
Quantity 2009

Product Description

MicroAire SmartRelease Endoscopic System, Endoscopic Carpal Tunnel Release, SmartRelease Handpiece, containing IFU rev. D The MicroAire Carpal Tunnel Release System is for use in patients diagnosed with carpal tunnel syndrome that is not associated with, or secondary to, any other known pathology (i.e., idiopathic carpal tunnel syndrome). Preoperative x-rays of the wrist, including a carpal tunnel view, are recommended to aid in the diagnosis of associated pathology (i.e., calcific tendonitis, fracture of the hook of the hamate). This device is indicated for releasing the transverse carpal ligament (flexor retinaculum).

Reason for Recall

The Instructions for Use (IFU) is incorrect with regards to sterilization parameters and must be replaced.

Distribution Pattern

Worldwide Distribution - USA (nationwide) including Puerto Rico and to the countries of: Australia, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, India, Iran, Ireland, Israel, Italy, Jordan, Korea, Lebanon, Mexico, Nicaragua, Poland, Russia, Saudi Arabia, Serbia, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, UAE, and UK.

Lot / Code Information

All products distributed from 1/1/13 to 2/23/18

Other Recalls from MicroAire Surgical Instruments, LLC

Recall # Classification Product Date
Z-1975-2025 Class II Brand Name: SmartRelease ESTR (Endoscopic soft ... May 7, 2025
Z-2222-2019 Class II SmartRelease Endoscopic Carpal Tunnel Release H... Jun 26, 2019
Z-0412-2018 Class II SST TWIST DRILL, STANDARD, 1.6mm Dia. x 127mm, ... May 22, 2017
Z-1407-2017 Class II MicroAire K-Wires Feb 21, 2017
Z-2294-2016 Class II Endotine Transbleph 3.5 (CFD-080-0167) May 6, 2016

Frequently Asked Questions

Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.